Floatz logo

Retifanlimab

Breast Neoplasm

BriaCell Therapeutics Corporationmonoclonal_antibodyPhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

176 Active assets in the Breast Neoplasm cohort.

Asset / SponsorPhaseRating
Inno-206
Merck Sharp & Dohme LLC
Phase 4BB
Letrozole
Fujian Cancer Hospital
Phase 4BB
TAMOXIFEN
Eli Lilly and Company
Phase 3BB
EXEMESTANE
Fujian Cancer Hospital
Phase 4BB
Docetaxel
Universitas Airlangga
Phase 4BB

View all 50 →

Same molecule, other indications

Retifanlimab is also rated in:

urothelial carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
anal canal squamous cell carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →